Z Squared Inc. quarterly report, Q1 FY2022

Business context and reporting period

Filing identity: The request metadata names Z Squared Inc., but the supplied 10-Q is for Bull Horn Holdings Corp. This summary reflects the filing provided. It covers the unaudited quarter ended March 31, 2022, with comparisons to the quarter ended March 31, 2021.

Bull Horn was a blank-check SPAC seeking a business combination, with a stated focus on sports, entertainment and brands. It had not commenced operating activities and had no operating revenue through the reporting date.

Financial results and position

MetricQ1 2022 / March 31, 2022Q1 2021 / December 31, 2021
Operating costs$419,783$141,518
Net income$3,184,794$14,072,850
Interest income on Trust Account securities$6,753$1,868
Gain from change in warrant fair value$3,597,824$14,212,500
Net cash used in operating activities$237,972$140,498
Cash outside Trust Account$166,373$404,345 at December 31, 2021
Trust Account marketable securities$75,765,534$75,758,781 at December 31, 2021
Current liabilities$363,863$139,927 at December 31, 2021
Warrant liabilities$1,199,176$4,797,000 at December 31, 2021
Deferred underwriting fee payable$2,250,000$2,250,000 at December 31, 2021
Working capital deficit$147,032Not stated as a comparable figure

Basic and diluted earnings per share were $0.34 in Q1 2022, versus $1.50 in Q1 2021. The reported profits largely reflect noncash warrant remeasurement gains, not operating revenue. The filing does not provide meaningful operating margins because the company had no operating revenue. Shareholders’ deficit was $3,580,674 at March 31, 2022.

Material changes versus the prior comparable period

  • Net income fell from $14.1 million to $3.2 million, principally because the warrant-liability fair-value gain was smaller; the gain declined from $14.2 million to $3.6 million.
  • Operating costs increased to $419,783 from $141,518.
  • Cash used in operations increased to $237,972 from $140,498, while cash outside the Trust Account declined by $237,972 during the quarter.
  • Warrant liabilities decreased to $1.2 million from $4.8 million, reflecting the fair-value remeasurement.

Outlook, risks and unusual items

  • Proposed transaction: On April 18, 2022, Bull Horn agreed to combine with Coeptis Therapeutics, Inc. The stated aggregate consideration is $175 million, adjusted for specified debt, cash and transaction expenses; consideration to Coeptis stockholders is to be paid in shares. Completion was not assured.
  • Extension and redemptions: Shareholders approved extending the business-combination deadline to November 3, 2022. After quarter-end, 4,258,586 public shares were redeemed for approximately $43.0 million, leaving approximately $32.7 million in the Trust Account and 3,241,414 public shares outstanding. The Sponsor agreed to provide monthly extension loans of approximately $66,667, up to $400,000 in total.
  • Underwriting fee: In May 2022, underwriters agreed to reduce the deferred fee from $2.25 million to $500,000, but only if the Coeptis transaction closes.
  • Liquidity and going concern: Management reported substantial doubt about the company’s ability to continue as a going concern if it fails to complete a business combination by the deadline and does not obtain a further extension. The company reported limited operating cash and a working capital deficit; the Trust Account is restricted primarily for a business combination or shareholder redemptions.
  • Accounting and controls: Management disclosed a material weakness in internal controls over accounting for complex financial instruments and redeemable shares, and concluded disclosure controls were not effective. The filing also describes restatements of earlier-period financial statements for redemption-value accounting; management said the correction did not affect cash.
  • Other risks: The filing cites potential effects from COVID-19, inflation, higher interest rates, market volatility, supply-chain disruption and geopolitical instability, as well as possible added SPAC regulatory requirements. Warrants are liability-classified and their remeasurement can materially affect reported earnings.
  • No formal financial guidance is provided. If no business combination is completed by the applicable deadline, the company expects to liquidate and redeem public shares; warrants may expire worthless.

Most important facts for investors to verify

  1. Confirm the intended issuer: the supplied filing is for Bull Horn Holdings Corp., not Z Squared Inc.
  2. Review the status, conditions, financing and final terms of the proposed Coeptis merger, including the treatment of Coeptis debt and transaction expenses.
  3. Verify post-redemption Trust Account funds, extension-loan deposits, remaining public shares and the transaction’s available cash at closing.
  4. Check whether the $500,000 deferred-underwriting-fee reduction applies, since it is conditional on completing the Coeptis transaction.
  5. Assess progress in remediating the disclosed material weakness and the implications of the prior-period restatements.
  6. Distinguish recurring cash needs from reported earnings, which were materially affected by noncash warrant fair-value gains.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.